UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
||
(Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 | Other Events. |
As previously reported, Miragen Therapeutics, Inc. (the “Company”) entered into an exclusive license agreement with ImmunoGen, Inc. (“ImmunoGen”) dated October 12, 2020 (the “License Agreement”), under which the Company has the exclusive worldwide rights to develop and commercialize VRDN-001 for all non-oncology indications that do not use radiopharmaceuticals, including the treatment of thyroid eye disease. Under the terms of the License Agreement, the Company made an upfront payment to Immunogen and may be obligated to make additional royalty payments upon reaching certain specified development and sales milestones.
The description provided above is only a brief summary of the material terms of the License Agreement and does not purport to be a complete description of the rights and obligations of the parties thereto. The summary description is qualified in its entirety by reference to the full text of the License Agreement, which is attached hereto as Exhibit 10.1 and incorporated by reference into this Item 8.01.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit |
Description | |
10.1 | License Agreement, by and between the Company and ImmunoGen, dated as of October 12, 2020*. | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* | Portions of this document have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. |
* * *
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Miragen Therapeutics, Inc. | ||||||
Date: December 9, 2020 | By: | /s/ Jason A. Leverone | ||||
Jason A. Leverone | ||||||
Chief Financial Officer, Treasurer, and Secretary |